Thomas M Bodenstine, Ph.D.

Assistant Professor
Downers Grove, IL

Home / Academics / Our Faculty / Thomas M Bodenstine, Ph.D.

Title
Assistant Professor

Campus
Downers Grove, IL

College
Chicago College of Pharmacy
College of Graduate Studies - IL
College of Health Sciences - IL

Department
Biochemistry and Molecular Genetics

Education

University of Alabama at Birmingham | 2010 | Ph.D.
Pennsylvania State University | 2004 | B.S.

Courses Taught

BIOCD 0510/0560/1554: Biochemistry I - Pharmacy, Masters

BIOCD 0520/0570/1555: Biochemistry II, Pharmacy, Masters

BIOCD 0551: Human Biochemistry, Physician Assistant

BIOCD 0530/0580/0581: Human Genetics, Physician Assistant, Masters

BIOCD 1553: Cell and Tissue Structure and Function, Physical Therapy (Course Director)

IBSSD 1501: Foundations of Cell Function, Dental

Research

Gap junctions are regulated intercellular pores formed by the connexin family of proteins that allow for passage of ions, signaling molecules and nutrients between epithelial cells. Proper regulation of gap junction communication contributes to cellular homeostasis and tissue function.

During cancer development, the normal roles of connexins are often dysregulated. Expression of connexin genes may be lost or connexin protein function may be altered. Collectively, these changes can affect how cancer cells function and respond to therapy. Interestingly, gap junction communication can be restored wtihin metastatic tumor cells by modulation of signaling pathways without the need for exogenous expression of connexin genes.

The focus of my laboratory aims to understand the pathway alterations that lead to changes in connexin function during breast cancer progression, and how this information may be used from a therapeutic standpoint.

Publications

Research Manuscripts

Bodenstine TM, Chandler GS, Reed DW, Margaryan NV, Gilgur A, Atkinson J, Ahmed N, Hyser M, Seftor EA, Strizzi L, Hendrix MJ. Nodal expression in triple-negative breast cancer: cellular effects of its inhibition following doxorubicin treatment. Cell Cycle 2016; 15(9):1295-302.

Bodenstine TM, Chandler GS, Seftor RE, Seftor EA, Hendrix MJ. Plasticity underlies tumor progression: Role of Nodal in Cancer. Cancer and Metastasis Reviews 2016; 35(1):21-39

Strizzi L, Sandomenico A, Margaryan NV, Focà A, Sanguigno L, Bodenstine TM, Chandler GS, Reed DW, Gilgur A, Seftor EA, Seftor RE, Khalkhali-Ellis Z, Leonardi A, Ruvo M, Hendrix MJ. Effects of a novel Nodal-targeting monoclonal antibody in melanoma. Oncotarget 2015; 6(33):34071-86.

Khalkhali-Ellis Z, Kirschmann DA, Seftor EA, Gilgur A, Bodenstine TM, Hinck AP, Hendrix MJ. Divergence(s) in nodal signaling between aggressive melanoma and embryonic stem cells. International Journal of Cancer 2015; 136:E242-E251.

Bodenstine TM, Seftor RE, Seftor EA, Khalkhali-Ellis Z, Samii NA, Monarrez JC, Chandler GS, Pemberton PA, Hendrix MJ. Internalization by multiple endocytic pathways and lysosomal processing impact Maspin-based therapeutics. Molecular Cancer Research 2014; 12:1480-1891.

Bodenstine TM, Seftor RE, Khalkhali-Ellis Z, Seftor EA, Pemberton PA, Hendrix MJ. Maspin: molecular mechanisms and therapeutic implications. Cancer and Metastasis Reviews 2012; 31: 529-551.

Bodenstine TM, Vaidya KS, Ismail A, Beck BH, Diers AR, Edmonds MD, Kirsammer GT, Landar A, Welch DR. Subsets of ATP-sensitive potassium channel (KATP) inhibitors increase gap junctional intercellular communication in metastatic cancer cell lines independent of SUR expression. FEBS Letters 2012; 586(1): 27-31.

Bodenstine TM, Beck BH, Cao X, Cook LM, Ismail A, Powers JK, Mastro AM, Welch DR. MC3T3-E1 promote breast cancer growth in bone in a murine xenograft model. Chinese Journal of Cancer 2011; 30(3): 189-96.

Bodenstine TM, Vaidya KS, Ismail A, Beck BH, Cook LM, Diers AR, Landar A, Welch DR. Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition. Cancer Research 2010; 70(23): 10002-10011.

Diers AR, Dranka BP, Ricart KC, Oh JY, Johnson MS, Zhou F, Pallero MA, Bodenstine TM, Murphy-Ullrich JE, Welch DR, Landar A. Modulation of mammary cancer cell migration by 15-deoxy-Δ12,14-prostaglandin J2: implications for anti-metastatic therapy. Biochemical Journal 2010; 430(1):69-78.

Frolova N, Edmonds MD, Bodenstine TM, Seitz R, Johnson MR, Feng R, Accavitti-Loper MA, Welch DR, Frost AR. A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers. Tumor Biology 2009; 30:148-159.

Bodenstine TM, Welch DR. Metastasis suppressors and the tumor microenvironment. Cancer Microenvironment 2008; 1:1-11.

Kim M, Bodenstine TM, Sumerel LA, Rivera AA, Baker AH and Douglas JT. Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo. Cancer Biology and Therapy 2006; 5:12, 1647-1653.

 

Book Chapters

Kristjansdottir K, Bodenstine TM, Noronha S. Chapter: Neoplasia. Advanced Physiology and Pathophysiology: Essentials for Clinical Practice. 2020; 215-240.

Strizzi L, Hardy KM, Bodenstine TM, Hendrix JC. Targeting tumor cell plasticity. Stem Cells Handbook, Second Edition, Humana Press Inc. 2013; 441-448.

 

Educational Manuscripts

Verdone M, Joshi MD, Bodenstine TM, Green JM, Lynch SM, Gettig JP, Fjortoft N. Impact of an online, self-directed pre-pharmacy bridging course on students’ academic performance. American Journal of Pharmaceutical Education 2020; ajpe7864.

Organizations

American Association for Cancer Research (AACR)

Metastasis Research Society (MRS)